These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 23075248)

  • 21. [Biological markers in the diagnosis of dementia and Alzheimer's disease].
    Meiner Z; Rosenmann H
    Harefuah; 2012 May; 151(5):289-93, 318. PubMed ID: 22844733
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
    Formichi P; Battisti C; Radi E; Federico A
    J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics.
    Zimmermann R; Lelental N; Ganslandt O; Maler JM; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2011; 25(4):739-45. PubMed ID: 21593568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurochemical dementia diagnostics: assays in CSF and blood.
    Lewczuk P; Hornegger J; Zimmermann R; Otto M; Wiltfang J; Kornhuber J
    Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():44-9. PubMed ID: 18985294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neurochemical early and differential diagnostics for Alzheimer's disease].
    Wiltfang J; Lewczuk P; Maler M; Bleich S; Smirnov A; Kornhuber J
    MMW Fortschr Med; 2004 Sep; 146(38):38-40. PubMed ID: 15532429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.
    Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S
    J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.
    Andreasen N; Blennow K
    Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Zetterberg H; Lunn MP; Herukka SK
    Biomark Med; 2012 Aug; 6(4):371-6. PubMed ID: 22917139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
    Otto M; Lewczuk P; Wiltfang J
    Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load.
    Wiltfang J; Esselmann H; Bibl M; Hüll M; Hampel H; Kessler H; Frölich L; Schröder J; Peters O; Jessen F; Luckhaus C; Perneczky R; Jahn H; Fiszer M; Maler JM; Zimmermann R; Bruckmoser R; Kornhuber J; Lewczuk P
    J Neurochem; 2007 May; 101(4):1053-9. PubMed ID: 17254013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biochemical markers for Alzheimer disease].
    Czarna JM; Waldemar G; Heegaard NH
    Ugeskr Laeger; 2006 Mar; 168(10):1010-4. PubMed ID: 16522291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A; Sindic CJ
    Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias.
    Blasko I; Lederer W; Oberbauer H; Walch T; Kemmler G; Hinterhuber H; Marksteiner J; Humpel C
    Dement Geriatr Cogn Disord; 2006; 21(1):9-15. PubMed ID: 16244482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
    Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
    Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
    Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
    Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The amyloid and tau hypothesis in degenerative dementia].
    Fladby T; Maehlen J
    Tidsskr Nor Laegeforen; 1999 Mar; 119(7):976-9. PubMed ID: 10210960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
    Sancesario GM; Cencioni MT; Esposito Z; Borsellino G; Nuccetelli M; Martorana A; Battistini L; Sorge R; Spalletta G; Ferrazzoli D; Bernardi G; Bernardini S; Sancesario G
    J Alzheimers Dis; 2012; 31(4):865-78. PubMed ID: 22717612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
    Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
    Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
    Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
    Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analytical aspects of molecular Alzheimer's disease biomarkers.
    Andreasson U; Vanmechelen E; Shaw LM; Zetterberg H; Vanderstichele H
    Biomark Med; 2012 Aug; 6(4):377-89. PubMed ID: 22917140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.